Obesity is a global health crisis with profound clinical and societal consequences, contributing to increased risks of chronic illness and related mortality.1 Despite being recognised as a disease by ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk Mexico and the Salvador Zubirán Institute signed a major agreement to develop clinical studies in ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Originally designed as glucose-lowering medications, SGLT2 inhibitors provide benefits across the cardio-renal-metabolic ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

No, Donald Trump was not the focus of attention this week, even though the US president invited people to a parade to ...

Recursion Pharmaceuticals ( RXRX -5.13%) is not the most famous artificial intelligence (AI) stock on the market, but the ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...